Therapeutic area intelligence for Coronary Artery Disease with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 2

Companies

Bayer →

cardiovascular therapeutics companies →

Assets

Identifying Unstable →

Recent signals(2)

ClinicalJune 26, 2026

Bayer's Study on Nitroglycerin and Nurandociguat Safety in CAD Patients

A clinical trial is underway to assess the safety and interaction of nitroglycerin and nurandociguat in patients with coronary artery disease.

ClinicalJune 22, 2026

New Strategy for Identifying Unstable Coronary Plaque in Emergency Chest Pain Patients

A study is underway to implement a primary prevention strategy using calcium scoring and 18F-Na PET scans to identify unstable coronary plaques in emergency department patients.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Coronary Artery Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.